Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 128

1.

Antiviral therapy reduces risk of hepatocellular carcinoma in patients with hepatitis C virus-related cirrhosis.

Singal AK, Singh A, Jaganmohan S, Guturu P, Mummadi R, Kuo YF, Sood GK.

Clin Gastroenterol Hepatol. 2010 Feb;8(2):192-9. doi: 10.1016/j.cgh.2009.10.026. Epub 2009 Oct 30. Review.

PMID:
19879972
2.
3.

Interferon and prevention of hepatocellular carcinoma in viral cirrhosis: an evidence-based approach.

Cammà C, Giunta M, Andreone P, Craxì A.

J Hepatol. 2001 Apr;34(4):593-602.

PMID:
11394661
4.

Development of hepatocellular carcinoma in patients with chronic hepatitis C who had a sustained virological response to interferon therapy: a multicenter, retrospective cohort study of 1124 patients.

Kobayashi S, Takeda T, Enomoto M, Tamori A, Kawada N, Habu D, Sakaguchi H, Kuroda T, Kioka K, Kim SR, Kanno T, Ueda T, Hirano M, Fujimoto S, Jomura H, Nishiguchi S, Seki S.

Liver Int. 2007 Mar;27(2):186-91.

PMID:
17311612
5.

Prevention of hepatocellular carcinoma and its recurrence in chronic hepatitis C patients by interferon therapy.

Omata M, Yoshida H, Shiratori Y.

Clin Gastroenterol Hepatol. 2005 Oct;3(10 Suppl 2):S141-3. Review.

PMID:
16234063
6.

Interferon therapy reduces the risk for hepatocellular carcinoma: national surveillance program of cirrhotic and noncirrhotic patients with chronic hepatitis C in Japan. IHIT Study Group. Inhibition of Hepatocarcinogenesis by Interferon Therapy.

Yoshida H, Shiratori Y, Moriyama M, Arakawa Y, Ide T, Sata M, Inoue O, Yano M, Tanaka M, Fujiyama S, Nishiguchi S, Kuroki T, Imazeki F, Yokosuka O, Kinoyama S, Yamada G, Omata M.

Ann Intern Med. 1999 Aug 3;131(3):174-81.

PMID:
10428733
7.

Reduced risk of hepatocellular carcinoma after interferon therapy in aged patients with chronic hepatitis C is limited to sustained virological responders.

Imai Y, Tamura S, Tanaka H, Hiramatsu N, Kiso S, Doi Y, Inada M, Nagase T, Kitada T, Imanaka K, Fukuda K, Takehara T, Kasahara A, Hayashi N.

J Viral Hepat. 2010 Mar;17(3):185-91. doi: 10.1111/j.1365-2893.2009.01163.x. Epub 2009 Aug 26.

PMID:
19709362
8.

Interferon therapy in chronic hepatitis B reduces progression to cirrhosis and hepatocellular carcinoma: a meta-analysis.

Yang YF, Zhao W, Zhong YD, Xia HM, Shen L, Zhang N.

J Viral Hepat. 2009 Apr;16(4):265-71. doi: 10.1111/j.1365-2893.2009.01070.x. Epub 2009 Feb 12.

PMID:
19220736
9.

The impact of antiviral therapy on the course of chronic HCV infection. A systematic review.

Almasio PL, Venezia G, Craxì A.

Panminerva Med. 2003 Sep;45(3):175-82. Review.

PMID:
14618115
10.

Treatment of chronic hepatitis C virus infection in patients with cirrhosis.

Zeuzem S.

J Viral Hepat. 2000 Sep;7(5):327-34. Review.

PMID:
10971820
11.

Risk factors for development of hepatocellular carcinoma in patients with chronic hepatitis C after sustained response to interferon.

Ikeda M, Fujiyama S, Tanaka M, Sata M, Ide T, Yatsuhashi H, Watanabe H.

J Gastroenterol. 2005 Feb;40(2):148-56.

PMID:
15770398
12.

Hepatocellular carcinoma appearance in patients with hepatitis C virus-related chronic liver disease 90 and 70 months after sustained virological response to interferon and ribavirin.

Vukotic R, Gramenzi A, Vitale G, Cursaro C, Serra C, Biselli M, Scuteri A, Andreone P, Bernardi M.

Liver Int. 2008 Mar;28(3):407-11. Epub 2007 Sep 26.

PMID:
17900241
13.

A sustained viral response is associated with reduced liver-related morbidity and mortality in patients with hepatitis C virus.

Singal AG, Volk ML, Jensen D, Di Bisceglie AM, Schoenfeld PS.

Clin Gastroenterol Hepatol. 2010 Mar;8(3):280-8, 288.e1. doi: 10.1016/j.cgh.2009.11.018. Epub 2009 Nov 27.

PMID:
19948249
14.

Combination of interferon and ribavirin in chronic hepatitis C: re-treatment of nonresponders to interferon.

Di Bisceglie AM, Thompson J, Smith-Wilkaitis N, Brunt EM, Bacon BR.

Hepatology. 2001 Mar;33(3):704-7.

PMID:
11230751
17.

Prolonged-interferon therapy reduces hepatocarcinogenesis in aged-patients with chronic hepatitis C.

Arase Y, Ikeda K, Suzuki F, Suzuki Y, Kobayashi M, Akuta N, Hosaka T, Sezaki H, Yatsuji H, Kawamura Y, Kobayashi M, Kumada H.

J Med Virol. 2007 Aug;79(8):1095-102.

PMID:
17597485
18.

Prevention of hepatitis C virus-related hepatocellular carcinoma.

Heathcote EJ.

Gastroenterology. 2004 Nov;127(5 Suppl 1):S294-302. Review.

PMID:
15508097
19.

Antiviral therapy for chronic hepatitis C in patients with inherited bleeding disorders: an international, multicenter cohort study.

Posthouwer D, Yee TT, Makris M, Fischer K, Griffioen A, Van Veen JJ, Mauser-Bunschoten EP.

J Thromb Haemost. 2007 Aug;5(8):1624-9.

20.

Interferon reduces the risk of hepatocellular carcinoma in hepatitis C virus-related chronic hepatitis/liver cirrhosis.

Masuzaki R, Yoshida H, Omata M.

Oncology. 2010 Jul;78 Suppl 1:17-23. doi: 10.1159/000315225. Epub 2010 Jul 8.

PMID:
20616579

Supplemental Content

Support Center